Reuters logo
BRIEF-Fortress Biotech says FDA has granted CEVA101 RMAT for treatment of traumatic brain injury
November 8, 2017 / 2:18 PM / in 15 days

BRIEF-Fortress Biotech says FDA has granted CEVA101 RMAT for treatment of traumatic brain injury

Nov 8 (Reuters) - Fortress Biotech Inc:

* Fortress Biotech announces Cellvation’s CEVA101 granted FDA regenerative medicine advanced therapy designation for the treatment of traumatic brain injury

* Fortress Biotech Inc - CEVA‍101 is currently being assessed in phase 2 clinical trials for severe TBI in children and adults​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below